Asimov Therapeutics and AGC Biologics struck a licensing and manufacturing agreement to commercialize Asimov’s LV Edge Packaging cell line at AGC’s Milan cell & gene center. The system embeds inducible viral genes in a HEK293 backbone and enables lentiviral production with a single‑plasmid transfection instead of the standard four‑plasmid approach. AGC will offer the LV Edge process to customers, aiming to reduce GMP plasmid costs, process complexity and supply‑chain risk. The tie‑up reflects growing CDMO demand for simplified, scalable viral vector production technologies as cell and gene pipelines advance through clinical and commercial phases.